**Table II**. Clinical response to oral vinorelbine

|  |  |  |  |
| --- | --- | --- | --- |
| **Patient**  **(n=23)\*** | **Reason to start Vinorelbine** | **Treatment duration (months)** | **Overall response**  **(clinical + initial RECIST assessment)** |
| 1 | PD | 12 | Stabilization |
| 2 | PD | 6 | Stabilization |
| 3 | PD + pain | 6 | Stabilization and pain control |
| 5 | PD | 6 | Stabilization |
| 7 | Pain | 21 | Stabilization and pain control |
| 8 | PD | 12 | Stabilization |
| 9 | PD | 36 | Stabilization |
| 10 | PD | 2 | Stabilization |
| 12 | PD | 12 | Stabilization |
| 13 | PD | 21 | Stabilization |
| 14 | PD | 6 | Stabilization |
| 15 | PD | 3 | Stabilization |
| 16 | PD | 12 | Stabilization |
| 17 | PD | 12 | Stabilization |
| 18 | PD + pain | 12 | Stabilization and pain control |
| 19 | PD | 36 | Stabilization |
| 21 | PD | 12 | Stabilization |
| 4 | PD + pain | 18 | Objective response + pain control |
| 11 | Pain | 10 | Objective response |
| 20 | PD | 36 | Objective response |
| 22 | Refusal of IV treatment | 9 | Objective response |
| 6 | PD | 9 | Failure (progression) |
| 23 | PD | 4 | Failure (progression) |

\* One patient non evaluable for early discontinuation (1 month)

PD: progressive disease